| |
|
|
|
|
|
|
|||
|
Blood, 1 September 2005, Vol. 106, No. 5, pp. 1762-1769. Prepublished online as a Blood First Edition Paper on May 19, 2005; DOI 10.1182/blood-2004-12-4631.
Submitted December 8, 2004
II. Department of Medicine, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany * Corresponding author; email: c.hoffmann{at}med2.uni-kiel.de.
This study was undertaken to analyse the differentiation profiles assessed by immunophenotyping in AIDS-related lymphoma (ARL) and their relation to the clinical course. Paraffin embedded sections of 89 ARL cases during 1989-2004 were stained immunohistochemically with antibodies to CD3, CD10, CD20, CD38, CD138/Syn-1, MUM1/IRF4, BCL-2, BCL-6, LMP-1, and Ki-67. Expression of CD10 and CD20 were associated with better overall survival (OS, p=0.009 and p=0.04, respectively). Expression of CD20 was associated with longer disease-free survival (DFS, p=0.03), whereas expression of CD138/Syn-1 was associated with shorter DFS (p=0.03). OS and DFS were worse in patients with immunophenotypic profiles related to post-germinal center (GC) differentiation (BCL-6 and CD10 negative, MUM1/IRF4 and/or CD138/Syn-1 positive) when compared to GC differentiation (p=0.01). When controlled for age-adjusted International Prognostic Index (IPI), prior AIDS-defining illness (ADI) and year of ARL diagnosis, a post-GC differentiation remained significantly associated with poor OS and DFS. Expression of CD10 was associated with a preserved immunocompetence whereas CD20 was less frequent in patients developing ARL while on highly active antiretroviral therapy (p=0.04). In summary, lack of CD20 or CD10 expression and a post-germinal center signature are associated with a worse prognosis in ARL.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2005 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||